Non-steroidal anti-inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E protein

European Journal of Neuroscience

Volumn 18, Issue 6, 2003, Pages 1428-1438

  Aleong, Rosanne ^a   Aumont, Nicole ^a   Dea, Doris ^a   Poirier, Judes ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Aspirin; Cyclooxygenase; Indomethacin; Rodent

Indexed keywords

2 (ACETOXYPHENYL)HEPT 2 YNYL SULFIDE; 2 (ACETOXYPHENYL)HEPT 2 YNYL SULFIDE PHENOL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; AMIDE; APOLIPOPROTEIN E; INDOMETACIN; INDOMETACIN DERIVATIVE; LM 4108; LM 4115; LM 4192; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; EXTRACELLULAR SPACE; GLIA CELL; NERVE CELL PLASTICITY; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ACRIDINE ORANGE; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; ASTROCYTES; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ECTODYSPLASINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; GALACTOSYLCERAMIDES; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; INHIBITORY CONCENTRATION 50; MEMBRANE PROTEINS; NEUROGLIA; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 0141705337     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2003.02869.x     Document Type: Article

References (84)

1. Ali, S.M., Dunn, E., Oostveen, J.A., Hall, E.D. & Carter, D.B. (1996) Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia. Brain Res. Mol. Brain Res., 38, 37-44.
2. Andersen, K., Launer, L.J., Ott, A., Hoes, A.W., Breteler, M.M. & Hofman, A. (1995) Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology, 45, 1441-1445.
3. PE Applied Biosystems (1997) User Bulletin no. 2: ABI PRISM 7700 Sequence Detection System. PE Applied Biosystems, Foster City, CA, USA.
4. Avramovich, Y., Amit, T. & Youdim, M.B.H. (2002) Non-steroidal antiinflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem., 277, 31466-31473.
5. Bannwarth, B., Netter, P., Lapicque, F., Pere, P., Thomas, P. & Gaucher, A. (1990) Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity. Eur. J. Clin. Pharmacol., 38, 343-346.
6. Beffert, U., Aumont, N., Dea, D., Lussier-Cacan, S., Davignon, J. & Poirier, J. (1999b) Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res. Mol. Brain Res., 68, 181-185.
7. Beffert, U., Cohn, J.S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J. & Poirier, J. (1999a) Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res., 843, 87-94.
8. Bellosta, S., Nathan, B.P., Orth, M., Dong, L.M., Mahley, R.W. & Pitas, R.E. (1995) Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem., 270, 27063-27071.
9. Bertrand, P., Poirier, J., Oda, T., Finch, C.E. & Pasinetti, G.M. (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res., 33, 174-178.
10. Bieche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R. & Vidaud, M. (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin. Chem., 45, 1148-1156.
11. Bonaldo, M.F., Lennon, G. & Soares, M.B. (1996) Normalization and subtraction: two approaches to facilitate gene discovery. Genome Res., 6, 791-806.
12. de Bont, N., Netea, M.G., Demacker, P.N., Kullberg, B.J., van der Meer, J.W. & Stalenhoef, A.F. (2000) Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur. J. Clin. Invest, 30, 818-822.
13. Boyles, J.K., Zoellner, C.D., Anderson, L.J., Kosik, L.M., Pitas, R.E., Weisgraber, K.H., Hui, D.Y., Mahley, R.W., Gebicke-Haerter, P.J. & Ignatius, M.J. (1989) A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest, 83, 1015-1031.
14. Brand, K., Mackman, N. & Curtiss, L.K. (1993) Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J. Clin. Invest, 91, 2031-2039.
15. Breitner, J.C., Gau, B.A., Welsh, K.A., Plassman, B.L., McDonald, W.M., Helms, M.J. & Anthony, J.C. (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology, 44, 227-232.
16. Breitner, J.C., Welsh, K.A., Helms, M.J., Gaskell, P.C., Gau, B.A., Roses, A.D., Pericak-Vance, M.A. & Saunders, A.M. (1995) Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging, 16, 523-530.
17. Breslow, J.L., McPherson, J., Nussbaum, A.L., Williams, H.W., Lofquist-Kahl, F., Karathanasis, S.K. & Zannis, V.I. (1982) Identification and DNA sequence of a human apolipoprotein E cDNA clone. J. Biol. Chem., 257, 14639-14641.
18. Broe, G.A., Grayson, D.A., Creasey, H.M., Waite, L.M., Casey, B.J., Bennett, H.P., Brooks, W.S. & Halliday, G.M. (2000) Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol., 57, 1586-1591.
19. Copeland, R.A., Williams, J.M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S. & Trzaskos, J.M. (1994) Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl Acad. Sci. USA, 91, 11202-11206.
20. Cummings, J.L., Vinters, H.V., Cole, G.M. & Khachaturian, Z.S. (1998) Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology, 51, S2-S17.
21. Derham, B.K. & Harding, J.J. (2002) Effects of modifications of alpha-crystallin on its chaperone and other properties. Biochem. J., 364, 711-717.
22. Dixon, W.J. (1953) Processing data for outliers. Biometrics, 9, 74-89.
23. Duan, H., Li, Z. & Mazzone, T. (1995) Tumor necrosis factor-alpha modulates monocyte/macrophage apolipoprotein E gene expression. J. Clin. Invest, 96, 915-922.
24. Fazio, S., Linton, M.F., Hasty, A.H. & Swift, L.L. (1999) Recycling of apolipoprotein E in mouse liver. J. Biol. Chem., 274, 8247-8253.
25. Gierse, J.K., Koboldt, C.M., Walker, M.C., Seibert, K. & Isakson, P.C. (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J., 339, 607-614.
26. Glockner, F., Meske, V. & Ohm, T. (2002) Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience, 114, 1103-1114.
27. Griffin, W.S., Stanley, L.C., Ling, C., White, L., MacLeod, V., Perrot, L.J., White, C.L. III & Araoz, C. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl Acad. Sci. USA, 86, 7611-7615.
28. Guillaume, D., Bertrand, P., Dea, D., Davignon, J. & Poirier, J. (1996) Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations. J. Neurochem., 66, 2410-2418.
29. Haga, S., Akai, K. & Ishii, T. (1989) Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. (Berl.), 77, 569-575.
30. Hansen, S.H., Jensen, M.E. & Bjomsdottir, I. (1998) Assay of acetylsalicylic acid and three of its metabolites in human plasma and urine using non-aqueous capillary electrophoresis with reversed electroosmotic flow. J. Pharm. Biomed. Anal., 17, 1155-1160.
31. Holtzman, D.M. & Fagan, A.M. (1998) Potential role of apoE in structural plasticity in the nervous system - implications for disorders of the central nervous system. Trends Cardiovasc. Med., 8, 250-255.
32. Hull, M., Fiebich, B.L., Lieb, K., Strauss, S., Berger, S.S., Volk, B. & Bauer, J. (1996) Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol. Aging, 17, 795-800.
33. Kalgutkar, A.S., Crews, B.C., Rowlinson, S.W., Garner, C., Seibert, K. & Marnett, L.J. (1998b) Aspirin-like molecules that covalently inactivate cyclooxygenase-2 [see comments]. Science, 280, 1268-1270.
34. Kalgutkar, A.S., Crews, B.C., Rowlinson, S.W., Marnett, A.B., Kozak, K.R., Remmel, R.P. & Marnett, L.J. (2000) Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl Acad. Sci. USA, 97, 925-930.
35. Kalgutkar, A.S., Kozak, K.R., Crews, B.C., Hochgesang, G.P. Jr & Marnett, L.J. (1998a) Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J. Med. Chem., 41, 4800-4818.
36. Kitamura, Y., Shimohama, S., Koike, H., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J. & Taniguchi, T. (1999) Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun., 254, 582-586.
37. Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K., Isakson, P.C. & Stallings, W.C. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents [published erratum appears in Nature 1997 February 6; 385 (6616): 555]. Nature, 384, 644-648.
38. Laskowitz, D.T., Goel, S., Bennett, E.R. & Matthew, W.D. (1997) Apolipoprotein E suppresses glial cell secretion of TNF alpha. J. Neuroimmunol., 76, 70-74.
39. Laskowitz, D.T., Thekdi, A.D., Thekdi, S.D., Han, S.K., Myers, J.K., Pizzo, S.V. & Bennett, E.R. (2001) Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol., 167, 74-85.
40. Lynch, J.R., Morgan, D., Mance, J., Matthew, W.D. & Laskowitz, D.T. (2001) Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J. Neuroimmunol., 114, 107-113.
41. Mahley, R.W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science, 240, 622-630.
42. Masliah, E., Mallory, M., Veinbergs, I., Miller, A. & Samuel, W. (1996) Alterations in apolipoprotein E expression during aging and neurodegeneration. [Review]. Prog. Neurobiol., 50, 493-503.
43. McGeer, P.L., McGeer, E., Rogers, J. & Sibley, J. (1990) Anti-inflammatory drugs and Alzheimer disease [letter]. Lancet, 335, 1037.
44. McLean, J.W., Fukazawa, C. & Taylor, J.M. (1983) Rat apolipoprotein E mRNA. Cloning and sequencing of double-stranded cDNA. J. Biol. Chem., 258, 8993-9000.
45. Meade, E.A., Smith, W.L. & DeWitt, D.L. (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 268, 6610-6614.
46. Morgan, T.E., Laping, N.J., Rozovsky, I., Oda, T., Hogan, T.H., Finch, C.E. & Pasinetti, G.M. (1995) Clusterin expression by astrocytes is influenced by transforming growth factor beta 1 and heterotypic cell interactions. J. Neuroimmunol., 58, 101-110.
47. Nakai, M., Kawamata, T., Taniguchi, T., Maeda, K. & Tanaka, C. (1996) Expression of apolipoprotein E mRNA in rat microglia. Neurosci. Lett., 211, 41-44.
48. Nathan, B.P., Bellosta, S., Sanan, D.A., Weisgraber, K.H., Mahley, R.W. & Pitas, R.E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science, 264, 850-852.
49. Overmyer, M., Helisalmi, S., Soininen, H., Laakso, M., Riekkinen, P.Sr & Alafuzoff, I. (1999) Astrogliosis and the ApoE genotype, an immunohistochemical study of postmortem human brain tissue. Dement. Geriatr. Cogn. Disord., 10, 252-257.
50. Panza, F., Solfrizzi, V., Colacicco, A.M., Basile, A.M., D'Introno, A., Capurso, C., Sabba, M., Capurso, S. & Capurso, A. (2003) Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. Neuroreport, 14, 605-608.
51. Pasinetti, G.M. & Aisen, P.S. (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience, 87, 319-324.
52. Perlmutter, L.S., Scott, S.A., Barron, E. & Chui, H.C. (1992) MHC class II-positive microglia in human brain: association with Alzheimer lesions [published erratum appears in J Neurosci. Res. 1993 June 15; 35 (3): 346]. J. Neurosci. Res., 33, 549-558.
53. Picot, D., Loll, P.J. & Garavito, R.M. (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 [see comments]. Nature, 367, 243-249.
54. Poirier, J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci., 17, 525-530.
55. Poirier, J. (2002) Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer's Disease: From risk factors to therapeutic targets. In Gauthier, S. & Cummings, J.L. (eds), Alzheimer's Disease and Related Disorders Annual. Dunitz, New York, pp. 1-23.
56. Poirier, J., Baccichet, A., Dea, D. & Gauthier, S. (1993b) Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience, 55, 81-90.
57. Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P. & Gauthier, S. (1993a) Apolipoprotein E polymorphism and Alzheimer's disease [see comments]. Lancet, 342, 697-699.
58. Poirier, J., Hess, M., May, P.C. & Finch, C.E. (1991) Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res., 11, 97-106.
59. Poirier, J., Minnich, A. & Davignon, J. (1995) Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Ann. Med., 27, 663-670.
60. Poirier, J. & Panisset, M. (2002) Apolipoprotein E: a novel therapeutic target for the treatment of Alzheimer's disease. Adv. Behav. Biol., 51, 39-43.
61. Price, J.L., Ko, A.I., Wade, M.J., Tsou, S.K., McKeel, D.W. & Morris, J.C. (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol., 58, 1395-1402.
62. Rall, S.C. Jr, Weisgraber, K.H. & Mahley, R.W. (1982) Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem., 257, 4171-4178.
63. Rensen, P.C., Jong, M.C., van Vark, L.C., van der Boom, H., Hendriks, W.L., van Berkel, T.J., Biessen, E.A. & Havekes, L.M. (2000) Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem., 275, 8564-8571.
64. Rome, L.H. & Lands, W.E. (1975) Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl Acad. Sci. USA, 72, 4863-4865.
65. Roth, G.J., Stanford, N. & Majerus, P.W. (1975) Acetylation of prostaglandin synthase by aspirin. Proc. Natl Acad. Sci. USA, 72, 3073-3076.
66. Saitoh, T., Kang, D., Mallory, M., DeTeresa, R. & Masliah, E. (1997) Glial cells in Alzheimer's disease: preferential effect of APOE risk on scattered microglia. Gerontology, 43, 109-118.
67. Scharf, S., Mander, A., Ugoni, A., Vajda, F. & Christophidis, N. (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology, 53, 197-201.
68. Shen, X., Xia, Y., Sass, C., Visvikis, S. & Siest, G. (1998) Association of apolipoprotein E polymorphism and concentration with serum lipids and apolipoprotein level in the Chinese from Shanghai. Clin. Chem. Lab. Med., 36, 615-619.
69. Sheng, J.G., Ito, K., Skinner, R.D., Mrak, R.E., Rovnaghi, C.R., Van Eldik, L.J. & Griffin, W.S. (1996) In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging, 17, 761-766.
70. Starck, M., Bertrand, P., Pepin, S., Schiele, F., Siest, G. & Galteau, M.M. (2000) Effects of pro-inflammatory cytokines on apolipoprotein E secretion by a human astrocytoma cell line (CCF-STTG1). Cell Biochem. Funct., 18, 9-16.
71. Stewart, W.F., Kawas, C., Corrada, M. & Metter, E.J. (1997) Risk of Alzheimer's disease and duration of NSAID use [see comments]. Neurology, 48, 626-632.
72. Stone, D.J., Rozovsky, I., Morgan, T.E., Anderson, C.P., Hajian, H. & Finch, C.E. (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol., 143, 313-318.
73. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak, V.M., Enghild, J., Salvesen, G.S. & Roses, A.D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA, 90, 1977-1981.
74. Swift, L.L., Farkas, M.H., Major, A.S., Valyi-Nagy, K., Linton, M.F. & Fazio, S. (2001) A recycling pathway for resecretion of internalized apolipoprotein E in liver cells. J. Biol. Chem., 276, 22965-22970.
75. Utermann, G., Langenbeck, U., Beisiegel, U. & Weber, W. (1980) Genetics of the apolipoprotein E system in man. Am. J. Hum. Genet., 32, 339-347.
76. Van Oosten, M., Rensen, P.C., Van Amersfoort, E.S., Van Eck, M., van Dam, A.M., Breve, J.J., Vogel, T., Panet, A., van Berkel, T.J. & Kuiper, J. (2001) Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J. Biol. Chem., 276, 8820-8824.
77. Veinbergs, I., Mante, M., Jung, M.W., Van Uden, E. & Masliah, E. (1999) Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 23, 519-531.
78. Walker, D.G. & McGeer, P.L. (1992) Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res. Mol. Brain Res., 14, 109-116.
79. Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulter, T., Kang, D.E., Marquez-Sterling, N., Golde, T.E. & Koo, E.H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature, 414, 212-216.
80. Winer, J., Jung, C.K., Shackel, I. & Williams, P.M. (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem., 270, 41-49.
81. Wisniewski, T., Lalowski, M., Baumann, M., Rauvala, H., Raulo, E., Nolo, R. & Frangione, B. (1996) HB-GAM is a cytokine present in Alzheimer's and Down's syndrome lesions. Neuroreport, 7, 667-671.
82. Wood, J.A., Wood, P.L., Ryan, R., Graff-Radford, N.R., Pilapil, C., Robitaille, Y. & Quirion, R. (1993) Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res., 629, 245-252.
83. Xu, P.T., Gilbert, J.R., Qiu, H.L., Ervin, J., Rothrock-Christian, T.R., Hulette, C. & Schmechel, D.E. (1999) Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol., 154, 601-611.
84. 2 receptor antagonists. Neurology, 59, 880-886.